CorMedix Inc. (CRMD)
Nasdaq · Healthcare · Biotechnology
$7.26+0.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $566M
- P/E (trailing)
- 3.5
- Forward P/E
- 20.7
- 52-week range
- $6.13 – $13.02
- 52-week change
- −35.17%
- EPS (trailing)
- $2.05
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $312M (+617.04%)
- Net income
- $163M
- Operating margin
- 48.2%
- Diluted EPS
- $2.04
- Free cash flow
- $173M
From the company’s annual report on SEC EDGAR.
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Headquarters: Parsippany, United States · 191 employees · cormedix.com